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Abstract
We evaluated factors influencing time to CD4 + T cell counts > 200 cells/mm3 in HIV-infected individuals with
CD4 + T cell < 50 cells/mm3 starting combination antiretroviral therapy (cART). We included a total of 29
patients on successful cART for more than 1 year. In a logistic regression model, higher pre-cART CD4 + T cell
counts were significantly associated with shorter time to CD4 + T cell counts > 200cells/mm3 in HIV-infected
individuals with baseline CD4 + T cell < 50 cells/mm3. In survival analysis, patients having higher pre-cART
CD4 + T cell counts, especially 40–49 cells/mm3, were at significantly higher risk of achieving CD4 + T cell
counts > 200 cells/mm3.
Introduction
Survival in human immunodeficiency virus (HIV)-infected individuals has improved with the introduc-
tion of combination antiretroviral therapy (cART).1,2
However, late diagnosis of HIV infection still contributes to
poor medical outcomes and the continuation of viral trans-
mission.3–5
Of the immunologic markers, the CD4 + T cell levels are not
only comprehensively used for initiating HIV therapy and
prophylaxis for opportunistic infections,6,7 but also are an
important criterion for categorizing HIV-related clinical con-
ditions.8,9 HIV-infected patients with CD4 + T cell counts
< 200 cells/mm3 are at risk for developing Pneumocystis in-
fections.7 In particular, CD4 + T cell counts < 50 cells/mm3 are
predisposing factors for all opportunistic infections (OIs) in-
cluding Mycobacterium avium complex (MAC) and cytomeg-
alovirus (CMV) infections.7 Thus, in HIV-infected
individuals, to prevent opportunistic infections it is important
that CD4+ T cell counts are increased to > 200 cells/mm3 as
soon as possible.
However, to our knowledge, little is known about factors
influencing time to CD4 + T cell counts > 200 cells/mm3 in
HIV-infected individuals with baseline CD4+ T cell counts
< 50 cells/mm3 at the start of cART.
Materials and Methods
A retrospective case-control study was conducted at an
urban hospital in Seoul, South Korea. HIV-1-infected persons,
who started cART between 1996 and 2010, were aged 18 years
or older at treatment initiation, had CD4+ T cell counts <50
cells/mm3 at the time of starting cART, and had sustained vi-
rological suppression (HIVRNA<400 copies/ml) over 1 year of
cART were eligible for this study. Patients who had any treat-
ment interruption for more than 1 month were excluded. CD4+
T cell counts of each individual were evaluated every 3 months
(within a window of–1 month). The pre-cART CD4+ T cell
counts were mostly measured when the treatment was started.
During this study, 593 HIV-infected patients were retro-
spectively analyzed. Among these patients, death and
follow-up loss were 31 and 265, respectively. Also, the study
included nine treatment-naive patients. The study included
288 patients who started cART as well, and 75 of these 288
patients had interruptions of treatment or virological failures.
Among 222 patients who had maintained a suppressed viral
load over 1 year after initiating cART were 29 HIV-infected
patients who had CD4 + T cell counts < 50 cells/mm3 at the
time of starting cART. All enrolled patients were initially
treated with cART at CD4+ T cell counts < 50 cells/mm3 due
to late diagnosis of HIV infection.
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The following variables were assessed: age at therapy ini-
tiation (years); gender; reported route of infection; prior ac-
quired immunodeficiency syndrome (AIDS) diagnosis at
cART initiation; hepatitis B or C coinfection; tuberculosis (TB)
coinfection during the follow-up; antiretroviral therapy (ART)
regimens [two nucleoside analog reverse transcriptase in-
hibitors (NRTIs) +nonnucleoside reverse transcriptase inhib-
itor (NNRTI), two NRTIs +protease inhibitor (PI), or other
combination] at cART initiation; CD4 + T cell count (cells/
mm3), CD8+ T cell count (cells/mm3), and HIV viral load
(copies/ml) at cART initiation. The Centers for Disease Con-
trol and Prevention (CDC) classification was determined for
each individual.10 The most severe CDC category recorded
was listed as the clinical status.
We estimated duration (months) from the initiation of
cART to the date of test reporting CD4+ T cell counts > 200
cells/mm3 in each individual. Patients were then categorized
into two groups depending on the median time to increase
from CD4+ T cell counts < 50 cells/mm3 to > 200 cells/mm3
after starting cART. One group was deemed the slow increase
group as its interval times were more than the median time
and the other group was deemed the fast increase group as its
interval times were faster than the median time. Pre-cART
CD4 + T cell counts were mostly measured when cART was
started. Even though pre-cART CD4 + T cell counts were
measured within 2 weeks before initiating cART in eight pa-
tients, there were four cases of the slow increase group and
four cases of the fast increase group.
To evaluate predictors of slow increase, we performed lo-
gistic regression analyses. Variables with a p-value of < 0.1 in
the univariate analysis were included for the multivariate
analysis. We also evaluated outcomes of CD4 + T cell count
> 200 cells/mm3 following cART initiation using a survival
analysis method. The survivor function for CD4 + T cell count
> 200 cells/mm3 was compared using Cox proportional haz-
ard models. Time was calculated from the initiation of cART
and ended at the time of reporting CD4 + T cell counts > 200
cells/mm3. The final multivariate model included all covari-
ates that remained significant at the 0.10 level (two sided). The
analyses were performed using SPSS (version 18).
Results
A total of 29 patients who fulfilled the inclusion criteria
were identified. The median age was 50 (range, 35–75) years,
and 96.6% (28/29) of the subjects were male. The most com-
mon exposure category wasmen having sex with men (MSM)
(44.8%), followed by heterosexual contact (10.4%). These 29
patients had achieved an absolute level of CD4 counts of 200
cells/mm3 and had a median interval time of 12 (range, 3–42)
months up to > 200 cells/mm3 of CD4 + T cell counts after
cART. Slow (n = 15) and fast (n = 14) increase groups had
median interval times of 18.3 and 3.5 months, respectively.
The demographic and clinical characteristics of each group
are shown in Table 1. Compared with patients who exhibited
a fast increase in CD4 + T cell counts, patients who showed a
slow increase had significantly lower pre-cART CD4 + T cell
counts. Only the slow increase group had TB coinfections. In
the multivariate analysis, lower pre-cART CD4+ T cell count
was significantly associated with the slow increase of CD4 + T
cell counts > 200 cells/mm3 (odds ratio 0.873; 95% confidence
interval 0.781–0.975; p = 0.016) (Table 2).
We also evaluated the factors associated with the time to the
increase of CD4+ T cell counts > 200 cells/mm3 since cART
initiation in Cox proportional hazard analysis. In the multi-
variate model, patients having a higher pre-cART CD4+ T cell
count, especially those whose baseline count was greater than
40 cells/mm3, had a significantly higher rate of CD4+ T cell
counts > 200 cells/mm3 (adjusted hazard ratio 6.633; 95%
confidence interval 1.121–39.230; p= 0.037) (Table 3).
Table 1. The Demographic and Clinical Characteristics of HIV-Infected Individuals with CD4+
T Cell < 50 Cells/mm3 at the Start of Combination Antiretroviral Therapy
Variables
Slow increase group
N= 15, n (%)
Fast increase group
N= 14, n (%)
Total
N = 29, n (%) p-value
Male gender 14 (93.3) 14 (100) 28 (96.6) 1.000
Age at starting cART, median, years (range) 47 (35–79) 51 (35–75) 50 (35–75) 0.323
Mode of transmission
Homosexual contacts 8 (53.3) 5 (35.7) 13 (44.8) 0.462
Heterosexual contacts 2 (13.3) 1 (7.1) 3 (10.4) 1.000
Unknown and othersa 5 (33.3) 8 (57.1) 13 (44.8)
Pre-cART CD4 + T cell count, median (IQR), cells/mm3 14 (6–18) 28 (6–47) 17 (10–29) 0.032
Pre-cART VL, median (IQR), log10 copies/ml 5.36 (4.72–5.69) 5.31 (3.88–6.30) 5.34 (4.82–5.34) 0.921
Pre-cART CD8 + T cell count, median (IQR), cells/mm3 370 (197–456) 493 (279–748) 413 (222–664) 0.076
Initial cART regimen
PI plus 2 NRTIs 7 (46.7) 6 (42.9) 16 (55.2) 0.837
NNRTI plus 2 NRTIs 8 (53.3) 8 (57.1) 13 (44.8) 0.837
TB coinfection at starting cART 3 (20.0) 0 (0.0) 3 (10.3) 0.224
HBV coinfection at starting cART 0 (0.0) 2 (14.3) 2 (6.9) 0.224
CDC stage at starting cART
B3 3 (20.0) 1 (7.1) 4 (13.8) 0.598
C3 12 (80.0) 13 (92.9) 25 (86.2) 0.598
aUnknown and others: 12 unknown and 1 blood product.
HIV, human immunodeficiency virus; cART, combination antiretroviral therapy; IQR, interquartile range; VL, viral load; PI, protease
inhibitor; NRTI, nucleoside analog reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; TB, tuberculosis;
HBV, hepatitis B virus; CDC, Centers for Disease Control and Prevention.
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Discussion
The CD4 + T cell count is an important determinant of
disease stage and prognosis in HIV-infected individuals.8,9
According to Lee et al., the proportion of individuals with a
late diagnosis defined by aCD4+ T cell count < 200 cells/mm3
at the time of diagnosis increased annually from 2000 to 2007
in South Korea.11 Late diagnosis, especially CD4 + T cell count
< 50 cells/mm3 at the time of diagnosis, results in delayed
treatment, increasing OIs, and an increased risk of transmis-
sion.3–5 Thus, there is still a high risk of mortality in HIV-
infected individuals due to late diagnosis.3–5
The factors that affect the extent of the increase of CD4+ T
cell counts in patients receiving cART have been studied. Some
have reported that the baseline CD4+ T cell count influences
the rate of immune reconstitution,12,13 whereas others have
found no evidence of such an association.14,15 However, to our
knowledge, little is known about HIV-infected individuals
with pre-cART CD4+ T cells < 50 cells/mm3, which was a
predisposing factor of all OIs including MAC and CMV in-
fections. To the best of our knowledge, our study represents the
first report regarding factors influencing time to reach CD4+ T
cell counts > 200 cells/mm3 in HIV-infected individuals with
CD4+ T cell counts < 50 cells/mm3 at the time of starting ART.
In this study, pre-cART CD4 + T cell counts were signifi-
cantly associated with time to CD4 + T cell counts > 200 cells/
mm3 in HIV-infected individuals with CD4 + T cell counts
< 50 cells/mm3 at the time of starting cART. In other words,
the lower the pre-cART CD4 + T cell counts among patients
with CD4 + T cell counts < 50 cells/mm3, the slower was the
increase of CD4 + T cell counts > 200 cells/mm3.
Also, we evaluated the impact of pre-cART CD4 + T cell
counts in patients with CD4 + T cell counts < 50 cells/mm3 at
the time of achieving a CD4+ T cell count > 200 cells/mm3
using survival analyses. Compared to those who started with
a CD4 of 0–10 cells/mm3, a pre-cARTCD4 + T cell count of 40–
49 cells/mm3 showed a higher rate of achieving a CD4 + T cell
count > 200 cells/mm3. Moreover, pre-cART CD4 + T cell
counts of 30–39 cells/mm3 showed a tendency to be greater
in achieving CD4 + T cell counts > 200 cells/mm3 ( p-value =
0.057). Therefore, in late diagnoses, especially for CD4 + T cell
counts < 40 cells/mm3, we need to immediately consider
cART and bemore aware of OIs and viral transmission during
cART. However, the results of this study are based on a small
sample size, so if more samples are added, more precise sta-
tistical significance can be identified.
Also, in our study, TB was observed in three patients in
only the slow increase group and none in the fast increase
Table 2. Multivariate Analysis of Time to CD4 + T Cell Counts > 200 Cells/mm3 After Combination
Antiretroviral Therapy in HIV-Infected Individuals with Baseline CD4 + T Cell < 50 Cells/mm3
Variables
Slow increase
group N= 15
Fast increase
group N= 14
Odds ratio
(95% CIs) p-value
Age at starting cART (per 1 year increase), median, years (range) 47 (35–79) 51 (35–75) 1.045 (0.948–1.152) 0.375
Pre-cART CD8 + T cell counts (per 100 cells/mm3 increase),
median (IQR), cells/mm3
14 (6–18) 28 (6–47) 0.888 (0.657–1.201) 0.442
Pre-cART CD4 + T cell counts (per 1 cell/mm3 increase),
median (IQR), cells/mm3
370 (197–456) 493 (279–748) 0.873 (0.781–0.975) 0.016
cART, combination antiretroviral therapy; IQR, interquartile range; HIV, human immunodeficiency virus; CIs, confidence intervals.
Table 3. Cox Proportional Hazards Analysis of an Increase of CD4+ T Cell count > 200 Cells/mm3
Following Combination Antiretroviral Therapy Initiation
Variables
Median time to
event (months)
n (%) of events
(CD4 > 200 cells/mm3)
Unadjusted
HR (95% CI)
p-
value
Adjusted
HR (95% CI) p-value
Age at starting cART, years
£ 50 10.5 15 (51.7) 1 1
50 > 9.7 14 (48.3) 0.897 (0.418–1.924) 0.78 0.874 (0.374–2.041) 0.756
Mode of transmission
Homosexual contacts 10.9 13 (44.8) 1 — —
Heterosexual contacts 11.7 3 (10.4) 1.362 (0.378–4.912) 0.637 — —
Pre-cART CD4 + T cell count, cells/mm3
< 10 17.4 7 (24.1) 1 1
10–19 11.7 12 (41.4) 1.001 (0.380–2.640) 0.998 0.990 (0.374–2.618) 0.983
20–29 8.3 3 (10.3) 2.404 (0.591–9.789) 0.221 2.234 (0.511–9.753) 0.285
30–39 9.7 5 (17.2) 3.594 (0.980–13.180) 0.054 3.538 (0.963–12.996) 0.057
40–49 2.7 2 (7.0) 6.25 (1.102–35.461) 0.039 6.633 (1.121–39.230) 0.037
Initial cART regimen
PI plus 2 NRTIs 10.5 13 (44.8) 1 — —
NNRTI plus 2 NRTIs 13.1 16 (55.2) 0.774 (0.365–1.638) 0.503 — —
cART, combination antiretroviral therapy; HR, hazard ratio; CIs, confidence intervals; VL, viral load; IQR, interquartile range; PI, protease
inhibitor; NRTI, nucleoside analog reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
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group. However, there was no significant association between
TB and time to CD4 + T cell counts > 200 cells/mm3, although
several studies showed that TB influenced the increase of
CD4 + T cell counts during cART.16,17
Our study has several limitations. First, our results were
not applicable to females with HIV infection. Gender is a very
important epidemiological variable but in our data, women
comprised only 3%, so we did not consider gender in our data
analysis. This is due to the fact that HIV-infected women in
Korea are rare (only about 9%) and our study did not have
enough women.18 Second, the sample size was small. How-
ever, we have enhanced the power by subdividing the group
with smaller categories. Amulticenter study is under progress
for more concrete results. Third, as in all retrospective studies,
there is a potential for bias and inaccurate data collection.
Further prospective studies, with larger patient populations
involving multiple centers, are necessary to ascertain the rel-
evant influencing factors accurately. Fourth, although CD4+
T cell counts of each individual were evaluated every 3
months in the two groups, the time to achieve a CD4 + T cell
count > 200 cells/mm3 is likely to be affected by interval
censoring because of a window of – 1 month. Lastly, we used
a single CD4 + T cell count for each time point, and ‘‘the re-
gression to the mean’’ could bias our results.
In conclusion, the pre-cART CD4+ T cell count was sig-
nificantly associated with time to CD4 + T cell counts > 200
cells/mm3 in HIV-infected individuals with CD4 + T cell
counts < 50 cells/mm3 at the start of cART. Therefore, in late
diagnoses, especially for CD4 + T cell counts < 40 cells/mm3,
we need to immediately consider cART and be more aware of
OIs and viral transmission during cART.
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